Kidney and Renal Diseases Therapeutics Market to 2017 - Strong Pipeline and Unmet Need Due to Poor Safety Profiles to Create Opportunities for Growth

NEW YORK, Aug. 30, 2011 /PRNewswire/ --Reportlinker.com announces that a new market research report is available in its catalogue:

Kidney and Renal Diseases Therapeutics Market to 2017 - Strong Pipeline and Unmet Need Due to Poor Safety Profiles to Create Opportunities for Growth

http://www.reportlinker.com/p0555132/Kidney-and-Renal-Diseases-Therapeutics-Market-to-2017---Strong-Pipeline-and-Unmet-Need-Due-to-Poor-Safety-Profiles-to-Create-Opportunities-for-Growth.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Pathology

Summary

GBI Research's report, "Kidney and Renal Diseases Therapeutics Market to 2017 - Strong Pipeline and Unmet Need Due to Poor Safety Profiles to Create Opportunities for Growth", provides in-depth analysis of unmet needs, drivers and barriers that impact the global kidney and renal diseases therapeutics market. The report analyzes the markets for kidney and renal diseases therapeutics in the US, the top five countries in Europe (the UK, Germany, France, Italy and Spain) and Japan. Treatment usage patterns, sales, prices and volumes are forecast until 2017 for the key geographies as well as the leading therapeutic segments. Further, the report provides competitive benchmarking for the leading companies and analyzes the mergers, acquisitions and licensing agreements that shape the global markets.

Scope

The scope of this report includes -

- Annualized market data for the kidney and renal diseases therapeutics market from 2001 to 2010, forecast forward to 2017

- Analysis of the leading therapeutic segments.

- Analysis of the kidney and renal diseases therapeutics market in the leading geographies of the world, which include the US, the UK, Germany, France, Italy, Spain, and Japan

- Market characterization of the kidney and renal diseases therapeutics market including market size, annual cost of therapy, and treatment usage patterns

- Key drivers and barriers that have a significant impact on the market

- Coverage of pipeline molecules in various phases of drug development

- Competitive benchmarking of leading companies.

- Key M&A activities, licensing agreements, that have taken place between 2008 and 2010 in the global kidney and renal diseases therapeutics market

Reasons to buy

The report will enhance your decision making capability. It will allow you to -

- Align your product portfolio to the markets with high growth potential.

- Develop market-entry and market expansion strategies by identifying the leading therapeutic segments and geographic markets poised for strong growth.

- Reinforce R&D pipelines by identifying new target mechanisms which can produce first-in-class molecules with more efficiency and better safety.

- Develop key strategic initiatives by understanding the key focus areas of leading companies.

- Exploit in-licensing and out-licensing opportunities by identifying products that could fill portfolio gaps.

Table of Contents

1 Table of Contents

1 Table of Contents 3

1.1 List of Tables 6

1.2 List of Figures 8

2 Kidney and Renal Diseases Therapeutics Market to 2017 - Introduction 11

2.1 GBI Research Report Guidance 12

3 Kidney and Renal Diseases Therapeutics Market to 2017 - Market Overview 13

3.1 Introduction 13

3.2 Revenue Forecasts for the Global Kidney and Renal Disease Market 13

3.2.1 Revenue 13

3.2.2 Annual Cost of Treatment (ACT) 14

3.3 Treatment Usage Patterns 15

3.3.1 Diseased Population 16

3.3.2 Treatment Seeking Population 17

3.3.3 Diagnosis Population 18

3.3.4 Prescription Population 19

4 Kidney and Renal Diseases Therapeutics Market to 2017 - Geographical Landscape 20

4.1 Revenue Analysis by Geography 20

4.2 The US 21

4.2.1 Revenue 21

4.2.2 Annual Cost of Treatment 22

4.3 Top Five Countries of Europe 23

4.3.1 Revenue 23

4.3.2 Annual Cost of Treatment 24

4.4 Japan 25

4.4.1 Revenue 25

4.4.2 Annual Cost of Treatment 26

5 Kidney and Renal Diseases Therapeutics Market to 2017 - Therapeutic Landscape 27

5.1 Chronic Kidney Diseases Market 27

5.1.1 Introduction 27

5.1.2 Revenue 27

5.1.3 Annual Cost of Treatment 30

5.1.4 Treatment Usage Patterns 31

5.1.5 Drivers and Barriers for the Chronic Kidney Diseases Market 36

5.1.6 Drivers for the Chronic Kidney Disease Market 36

5.1.7 Barriers for the Chronic Kidney Disease Market 36

5.2 Renal Anemia Market 37

5.2.1 Introduction 37

5.2.2 Revenue 37

5.2.3 Annual Cost of Treatment 40

5.2.4 Treatment Usage Patterns 41

5.2.5 Drivers and Barriers for the Renal Anemia Market 46

5.2.6 Drivers for the Renal Anemia Market 46

5.2.7 Barriers for the Renal Anemia Market 46

5.3 Diabetic Nephropathy Market 47

5.3.1 Introduction 47

5.3.2 Revenue 47

5.3.3 Annual Cost of Treatment 50

5.3.4 Treatment Usage Patterns 51

5.3.5 Drivers and Barriers for the Diabetic Nephropathy Market 56

5.3.6 Drivers for the Diabetic Nephropathy Market 56

5.3.7 Barriers for the Diabetic Nephropathy Market 56

5.4 Acute Kidney Injury Market 57

5.4.1 Introduction 57

5.4.2 Revenue 58

5.4.3 Annual Cost of Treatment 60

5.4.4 Treatment Usage Patterns 61

5.4.5 Drivers and Barriers for the Acute Kidney Injury Market 66

5.4.6 Drivers for the Acute Kidney Injury Market 66

5.4.7 Barriers for the Acute Kidney Injury Nephropathy Market 66

6 Kidney and Renal Diseases Therapeutics Market to 2017 - Product Pipeline Analysis 67

6.1 Introduction 67

6.1.1 Research and Development Pipeline – Chronic Kidney Disease (CKD) 68

6.1.2 Research and Development Pipeline – Renal Anemia (RA) 74

6.1.3 Research and Development Pipeline – Diabetic Nephropathy (DN) 76

6.1.4 Research and Development Pipeline – Acute Kidney Injury (AKI) 79

6.2 Profiles of Promising Drugs in the Kidney and Renal Disease Market 82

6.2.1 AMG 223 82

6.2.2 AST-120 83

6.2.3 CellCept 84

6.2.4 Ferinject 85

6.2.5 Genz-644470 86

6.2.6 Hematide 87

6.2.7 HEPLISAV 87

6.2.8 Heptar 88

6.2.9 SBR759 89

6.2.10 Sulodexide 90

6.2.11 YM533 90

6.2.12 Zuragen 91

6.2.13 Olmetec 91

7 Kidney and Renal Diseases Therapeutics Market to 2017 - Competitive Landscape 93

7.1 Market Share Analysis 93

7.2 Amgen Inc. 94

7.2.1 Company Overview 94

7.2.2 Business Overview 94

7.2.3 SWOT Analysis 95

7.3 Merck & Co., Inc. 96

7.3.1 Company Overview 96

7.3.2 Business Overview 96

7.3.3 SWOT Analysis 97

7.4 Bristol-Myers Squibb Company 98

7.4.1 Company Overview 98

7.4.2 Business Overview 98

7.4.3 SWOT Analysis 99

7.5 Hoffmann-La Roche Inc. 100

7.5.1 Company Overview 100

7.5.2 Business Overview 100

7.5.3 SWOT Analysis 101

7.6 Shire Inc. 102

7.6.1 Company Overview 102

7.6.2 Business Overview 102

7.6.3 SWOT Analysis 103

8 Kidney and Renal Diseases Therapeutics Market to 2017 - M&A Landscape 104

8.1 M&A Deals 104

8.1.1 Deal Summary 105

8.1.2 Deals by Geography 107

8.2 Licensing Deals 108

8.2.1 Summary of Licensing Deals (2009-2010) 109

8.3 Co-development Deals 111

8.3.1 Summary of Co-development Deals (2009-2010) 112

9 Kidney and Renal Diseases Therapeutics Market to 2017 - Appendix 114

9.1 Market Definitions 114

9.2 Abbreviations 114

9.3 Research Methodology 115

9.3.1 Coverage 115

9.3.2 Secondary Research 116

9.3.3 Primary Research 116

9.3.4 Expert Panel Validation 117

9.4 Contact Us 118

9.5 Disclaimer 118

9.6 Sources 118

List of Tables

1.1 List of Tables

Table 1: Kidney and Renal Diseases Therapeutics Market, Global, Revenue ($bn), 2002-2010 14

Table 2: Kidney and Renal Diseases Therapeutics Market, Global, Revenue Forecasts ($bn), 2010-2017 14

Table 3: Kidney and Renal Diseases Therapeutics Market, Global, Annual Cost of Treatment ($), 2002-2010 14

Table 4: Kidney and Renal Diseases Therapeutics Market, Global, Annual Cost of Treatment ($), 2010-2017 14

Table 5: Kidney and Renal Diseases Therapeutics Market, Global, Treatment Usage Pattern (millions), 2002-2010 15

Table 6: Kidney and Renal Diseases Therapeutics Market, Global, Treatment Usage Pattern (millions), 2010-2017 16

Table 7: Kidney and Renal Diseases Therapeutics Market, Global, Revenue Analysis by Geography ($bn), 2002-2010 20

Table 8: Kidney and Renal Diseases Therapeutics Market, Global, Revenue Analysis by Geography ($bn), 2010-2017 21

Table 9: Kidney and Renal Diseases Therapeutics Market, The US, Revenue ($bn), 2002-2010 21

Table 10: Kidney and Renal Diseases Therapeutics Market, The US, Revenue Forecasts ($bn), 2010-2017 22

Table 11: Kidney and Renal Diseases Therapeutics Market, The US, Annual Cost of Treatment ($), 2002-2010 22

Table 12: Kidney and Renal Diseases Therapeutics Market, The US, Annual Cost of Treatment ($), 2010-2017 22

Table 13: Kidney and Renal Diseases Therapeutics Market, Top Five Countries of Europe, Revenue ($bn), 2002-2010 23

Table 14: Kidney and Renal Diseases Therapeutics Market, Top Five Countries of Europe, Revenue Forecasts ($bn), 2010-2017 23

Table 15: Kidney and Renal Diseases Therapeutics Market, Top Five Countries of Europe, Annual Cost of Treatment ($), 2002-2010 24

Table 16: Kidney and Renal Diseases Therapeutics Market, Top Five Countries of Europe, Annual Cost of Treatment ($), 2010-2017 24

Table 17: Kidney and Renal Diseases Therapeutics Market, Japan, Revenue ($bn), 2002-2010 25

Table 18: Kidney and Renal Diseases Therapeutics Market, Japan, Revenue Forecasts ($bn), 2010-2017 25

Table 19: Kidney and Renal Diseases Therapeutics Market, Japan, Annual Cost of Treatment ($), 2002-2010 26

Table 20: Kidney and Renal Diseases Therapeutics Market, Japan, Annual Cost of Treatment ($), 2010-2017 26

Table 21: Kidney and Renal Diseases Therapeutics Market, Global, Chronic Kidney Disease, Revenue ($bn), 2002-2010 28

Table 22: Kidney and Renal Diseases Therapeutics Market, Global, Chronic Kidney Disease, Revenue Forecasts ($bn), 2010-2017 28

Table 23: Kidney and Renal Diseases Therapeutics Market, Global, Chronic Kidney Disease, Revenue by Geography ($bn), 2002-2010 29

Table 24: Kidney and Renal Diseases Therapeutics Market, Global, Chronic Kidney Disease, Revenue by Geography ($bn), 2010-2017 29

Table 25: Kidney and Renal Diseases Therapeutics Market, Global, Chronic Kidney Disease, Annual Cost of Treatment by Geography ($), 2002-2010 30

Table 26: Kidney and Renal Diseases Therapeutics Market, Global, Chronic Kidney Disease, Annual Cost of Treatment by Geography ($), 2010-2017 30

Table 27: Kidney and Renal Diseases Therapeutics Market, Global, Chronic Kidney Disease, Treatment Usage Pattern (millions), 2002-2010 31

Table 28: Kidney and Renal Diseases Therapeutics Market, Global, Chronic Kidney Disease, Treatment Usage Pattern (millions), 2010-2017 32

Table 29: Kidney and Renal Diseases Therapeutics Market, Global, Renal Anemia, Revenue ($bn), 2002-2010 38

Table 30: Kidney and Renal Diseases Therapeutics Market, Global, Renal Anemia, Revenue Forecasts ($bn), 2010-2017 38

Table 31: Kidney and Renal Diseases Therapeutics Market, Global, Renal Anemia, Revenue by Geography ($bn), 2002-2010 39

Table 32: Kidney and Renal Diseases Therapeutics Market, Global, Renal Anemia, Revenue by Geography ($bn), 2010-2017 39

Table 33: Kidney and Renal Diseases Therapeutics Market, Global, Renal Anemia, Annual Cost of Treatment by Geography ($), 2002-2010 40

Table 34: Kidney and Renal Diseases Therapeutics Market, Global, Renal Anemia, Annual Cost of Treatment by Geography ($), 2010-2017 40

Table 35: Kidney and Renal Diseases Therapeutics Market, Global, Renal Anemia, Treatment Usage Pattern (millions), 2002-2010 41

Table 36: Kidney and Renal Diseases Therapeutics Market, Global, Renal Anemia, Treatment Usage Pattern (millions), 2010-2017 42

Table 37: Kidney and Renal Diseases Therapeutics Market, Global, Diabetic Nephropathy, Revenue ($bn), 2002-2010 48

Table 38: Kidney and Renal Diseases Therapeutics Market, Global, Diabetic Nephropathy, Revenue Forecasts ($bn), 2010-2017 48

Table 39: Kidney and Renal Diseases Therapeutics Market, Global, Diabetic Nephropathy, Revenue by Geography ($bn), 2002-2010 49

Table 40: Kidney and Renal Diseases Therapeutics Market, Global, Diabetic Nephropathy, Revenue by Geography ($bn), 2010-2017 49

Table 41: Kidney and Renal Diseases Therapeutics Market, Global, Diabetic Nephropathy, Annual Cost of Treatment by Geography ($), 2002-2010 50

Table 42: Kidney and Renal Diseases Therapeutics Market, Global, Diabetic Nephropathy, Annual Cost of Treatment by Geography ($), 2010-2017 50

Table 43: Kidney and Renal Diseases Therapeutics Market, Global, Diabetic Nephropathy, Treatment Usage Pattern (millions), 2002-2010 51

Table 44: Kidney and Renal Diseases Therapeutics Market, Global, Diabetic Nephropathy, Treatment Usage Pattern (millions), 2010-2017 52

Table 45: Kidney and Renal Diseases Therapeutics Market, Global, Acute Kidney Injury, Revenue ($bn), 2002-2010 58

Table 46: Kidney and Renal Diseases Therapeutics Market, Global, Acute Kidney Injury, Revenue Forecasts ($bn), 2010-2017 58

Table 47: Kidney and Renal Diseases Therapeutics Market, Global, Acute Kidney Injury, Revenue by Geography ($bn), 2002-2010 59

Table 48: Kidney and Renal Diseases Therapeutics Market, Global, Acute Kidney Injury, Revenue by Geography ($bn), 2010-2017 59

Table 49: Kidney and Renal Diseases Therapeutics Market, Global, Acute Kidney Injury, Annual Cost of Treatment by Geography ($), 2002-2010 60

Table 50: Kidney and Renal Diseases Therapeutics Market, Global, Acute Kidney Injury, Annual Cost of Treatment by Geography ($), 2010-2017 60

Table 51: Kidney and Renal Diseases Therapeutics Market, Global, Acute Kidney Injury, Treatment Usage Pattern (millions), 2002-2010 61

Table 52: Kidney and Renal Diseases Therapeutics Market, Global, Acute Kidney Injury, Treatment Usage Pattern (millions), 2010-2017 62

Table 53: Kidney and Renal Diseases Therapeutics Market, Global, Chronic Kidney Disease, R&D Pipeline, 2011 69

Table 54: Kidney and Renal Diseases Therapeutics Market, Global, Renal Anemia, R&D Pipeline, 2011 75

Table 55: Kidney and Renal Diseases Therapeutics Market, Global, Diabetic Nephropathy, R&D Pipeline, 2011 77

Table 56: Kidney and Renal Diseases Therapeutics Market, Global, Acute Kidney Injury, R&D Pipeline, 2011 80

Table 57: Kidney and Renal Diseases Therapeutics Market, Global, Major M&A Deals, 2004-2010 104

Table 58: Kidney and Renal Diseases Therapeutics Market, Global, Licensing Deals, 2004-2010 108

Table 59: Kidney and Renal Diseases Therapeutics Market, Global, Major Co-development Deals, 2004-2010 111

List of Figures

1.2 List of Figures

Figure 1: Kidney and Renal Diseases Therapeutics Market, Global, Revenue Forecasts ($bn), 2002-2017 13

Figure 2: Kidney and Renal Diseases Therapeutics Market, Global, Annual Cost of Treatment ($), 2002-2017 14

Figure 3: Kidney and Renal Diseases Therapeutics Market, Global, Treatment Usage Pattern (millions), 2002-2017 15

Figure 4: Kidney and Renal Diseases Therapeutics Market, Global, Diseased Population (millions), 2002-2017 16

Figure 5: Kidney and Renal Diseases Therapeutics Market, Global, Treatment Seeking Population (millions), 2002-2017 17

Figure 6: Kidney and Renal Diseases Therapeutics Market, Global, Diagnosed Population (millions), 2002-2017 18

Figure 7: Kidney and Renal Diseases Therapeutics Market, Global, Prescription Population (millions), 2002-2017 19

Figure 8: Kidney and Renal Diseases Therapeutics Market, Global, Revenue Analysis by Geography ($bn), 2002-2017 20

Figure 9: Kidney and Renal Diseases Therapeutics Market, The US, Revenue Forecasts ($bn), 2002-2017 21

Figure 10: Kidney and Renal Diseases Therapeutics Market, The US, Annual Cost of Treatment ($), 2002-2017 22

Figure 11: Kidney and Renal Diseases Therapeutics Market, Top Five Countries of Europe, Revenue Forecasts ($bn), 2002-2017 23

Figure 12: Kidney and Renal Diseases Therapeutics Market, Top Five Countries of Europe, Annual Cost of Treatment ($), 2002-2017 24

Figure 13: Kidney and Renal Diseases Therapeutics Market, Japan, Revenue Forecasts ($bn), 2002-2017 25

Figure 14: Kidney and Renal Diseases Therapeutics Market, Japan, Annual Cost of Treatment ($), 2002-2017 26

Figure 15: Kidney and Renal Diseases Therapeutics Market, Global, Chronic Kidney Disease, Revenue Forecasts ($bn), 2002-2017 28

Figure 16: Kidney and Renal Diseases Therapeutics Market, Global, Chronic Kidney Disease, Revenue by Geography ($bn), 2002-2017 29

Figure 17: Kidney and Renal Diseases Therapeutics Market, Global, Chronic Kidney Disease, Annual Cost of Treatment by Geography ($), 2002-2017 30

Figure 18: Kidney and Renal Diseases Therapeutics Market, Global, Chronic Kidney Disease, Treatment Usage Pattern (millions), 2002-2017 31

Figure 19: Kidney and Renal Diseases Therapeutics Market, Global, Chronic Kidney Disease, Diseased Population (millions), 2002-2017 32

Figure 20: Kidney and Renal Diseases Therapeutics Market, Global, Chronic Kidney Disease, Treatment Seeking Population (millions), 2002-2017 33

Figure 21: Kidney and Renal Diseases Therapeutics Market, Global, Chronic Kidney Disease, Diagnosed Population (millions), 2002-2017 34

Figure 22: Kidney and Renal Diseases Therapeutics Market, Global, Chronic Kidney Disease, Prescription Population (millions), 2002-2017 35

Figure 23: Kidney and Renal Diseases Therapeutics Market, Global, Chronic Kidney Diseases, Market Drivers and Barriers, 2010-2017 36

Figure 24: Kidney and Renal Diseases Therapeutics Market, Global, Renal Anemia, Revenue Forecasts ($bn), 2002-2017 38

Figure 25: Kidney and Renal Diseases Therapeutics Market, Global, Renal Anemia, Revenue by Geography ($bn), 2002-2017 39

Figure 26: Kidney and Renal Diseases Therapeutics Market, Global, Renal Anemia, Annual Cost of Treatment by Geography ($), 2002-2017 40

Figure 27: Kidney and Renal Diseases Therapeutics Market, Global, Renal Anemia, Treatment Usage Pattern (millions), 2002-2017 41

Figure 28: Kidney and Renal Diseases Therapeutics Market, Global, Renal Anemia, Diseased Population (millions), 2002-2017 42

Figure 29: Kidney and Renal Diseases Therapeutics Market, Global, Renal Anemia, Treatment Seeking Population (millions), 2002-2017 43

Figure 30: Kidney and Renal Diseases Therapeutics Market, Global, Renal Anemia, Diagnosed Population (millions), 2002-2017 44

Figure 31: Kidney and Renal Diseases Therapeutics Market, Global, Renal Anemia, Prescription Population (millions), 2002-2017 45

Figure 32: Kidney and Renal Diseases Therapeutics Market, Global, Renal Anemia, Market Drivers and Barriers, 2010-2017 46

Figure 33: Kidney and Renal Diseases Therapeutics Market, Global, Diabetic Nephropathy, Revenue Forecasts ($bn), 2002-2017 48

Figure 34: Kidney and Renal Diseases Therapeutics Market, Global, Diabetic Nephropathy, Revenue by Geography ($bn), 2002-2017 49

Figure 35: Kidney and Renal Diseases Therapeutics Market, Global, Diabetic Nephropathy, Annual Cost of Treatment by Geography ($), 2002-2017 50

Figure 36: Kidney and Renal Diseases Therapeutics Market, Global, Diabetic Nephropathy, Treatment Usage Pattern (millions), 2002-2017 51

Figure 37: Kidney and Renal Diseases Therapeutics Market, Global, Diabetic Nephropathy, Diseased Population (millions), 2002-2017 52

Figure 38: Kidney and Renal Diseases Therapeutics Market, Global, Diabetic Nephropathy, Treatment Seeking Population (millions), 2002-2017 53

Figure 39: Kidney and Renal Diseases Therapeutics Market, Global, Diabetic Nephropathy, Diagnosed Population (millions), 2002-2017 54

Figure 40: Kidney and Renal Diseases Therapeutics Market, Global, Diabetic Nephropathy, Prescription Population (millions), 2002-2017 55

Figure 41: Kidney and Renal Diseases Therapeutics Market, Global, Diabetic Nephropathy, Market Drivers and Barriers, 2010-2017 56

Figure 42: Kidney and Renal Diseases Therapeutics Market, Global, Acute Kidney Injury, Revenue Forecasts ($bn), 2002-2017 58

Figure 43: Kidney and Renal Diseases Therapeutics Market, Global, Acute Kidney Injury, Revenue by Geography ($bn), 2002-2017 59

Figure 44: Kidney and Renal Diseases Therapeutics Market, Global, Acute Kidney Injury, Annual Cost of Treatment by Geography ($), 2002-2017 60

Figure 45: Kidney and Renal Diseases Therapeutics Market, Global, Acute Kidney Injury, Treatment Usage Pattern (millions), 2002-2017 61

Figure 46: Kidney and Renal Diseases Therapeutics Market, Global, Acute Kidney Injury, Diseased Population (millions), 2002-2017 62

Figure 47: Kidney and Renal Diseases Therapeutics Market, Global, Acute Kidney Injury, Treatment Seeking Population (millions), 2002-2017 63

Figure 48: Kidney and Renal Diseases Therapeutics Market, Global, Acute Kidney Injury, Diagnosed Population (millions), 2002-2017 64

Figure 49: Kidney and Renal Diseases Therapeutics Market, Global, Acute Kidney Injury, Prescription Population (millions), 2002-2017 65

Figure 50: Kidney and Renal Diseases Therapeutics Market, Global, Acute Kidney Injury, Market Drivers and Barriers, 2010-2017 66

Figure 51: Kidney and Renal Diseases Therapeutics Market, Global, Product Pipeline by Phase (%), 2011 67

Figure 52: Kidney and Renal Diseases Therapeutics Market, Global, Chronic Kidney Disease, R&D Pipeline by Phase, 2011 68

Figure 53: Kidney and Renal Diseases Therapeutics Market, Global, Renal Anemia, R&D Pipeline by Phase, 2011 74

Figure 54: Kidney and Renal Diseases Therapeutics Market, Global, Diabetic Nephropathy, R&D Pipeline by Phase, 2011 76

Figure 55: Kidney and Renal Diseases Therapeutics Market, Global, Acute Kidney Injury, R&D Pipeline by Phase, 2011 79

Figure 56: Kidney and Renal Diseases Therapeutics Market, Global, Top Companies Share, (%), 2009 93

Figure 57: Kidney and Renal Diseases Therapeutics Market, Global, SWOT Analysis of Amgen Inc., 2011 95

Figure 58: Kidney and Renal Diseases Therapeutics Market, Global, SWOT Analysis of Merck & Co., Inc., 2011 97

Figure 59: Kidney and Renal Diseases Therapeutics Market, Global, SWOT Analysis of Bristol-Myers Squibb Company, 2011 99

Figure 60: Kidney and Renal Diseases Therapeutics Market, Global, SWOT Analysis of Roche, 2011 101

Figure 61: Kidney and Renal Diseases Therapeutics Market, Global, SWOT Analysis of Shire, 2011 103

Figure 62: Kidney and Renal Diseases Therapeutics Market, Global, Major M&A Deals by Geography, 2005-2010 107

Figure 63: Kidney and Renal Diseases Therapeutics Market, Global, Major Licensing Deals by Geography, 2005-2010 109

Figure 64: GBI Research Market Forecasting Model 117

Companies Mentioned

Amgen Inc.

Merck & Co., Inc.

Bristol-Myers Squibb Company

Hoffmann-La Roche Inc.

Shire Inc.

To order this report:

Pathology Industry: Kidney and Renal Diseases Therapeutics Market to 2017 - Strong Pipeline and Unmet Need Due to Poor Safety Profiles to Create Opportunities for Growth

Pathology Business News

More  Market Research Report

Check our  Industry Analysis and Insights

Nicolas Bombourg
Reportlinker
Email: [email protected]
US: (805)652-2626
Intl: +1 805-652-2626

SOURCE Reportlinker